Skip to main content

Advertisement

You are viewing the new article page. Let us know what you think. Return to old version

A comparison of the in vitro antimicrobial activity of liposomes containing meropenem and gentamicin

Abstract

The antimicrobial activity of eight cationic, two neutral and three anionic liposome compositions containing meropenem and gentamicin was tested in vitro in broth and serum medium. The cationic formulations showed better antibacterial efficacy against both Gram-positive and Gram-negative bacteria than the anionic and neutral ones, regardless of the encapsulated drug. The most effective formulations were the cationic PC/DOPE/DOTAP 3:4:3 and PC/Chol/DOTAP 3:4:3, as the MICs with meropenem were 2 to 4 times lower than those of the free drug.

Abbreviations

Chol:

cholesterol

DDAB:

dimethyldioctadecylammoniumbromide salt

DMPG:

1,2-dimyristoyl-sn-glycero-3-phosphoglycerol

DOPE:

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine

DOTAP:

1,2-dioleoyloxy-3-trimethyl ammonium-propane

DPPC:

1,2-diplamitoyl-sn-glycero-3-phosphocholine

GE:

gentamicin

MEM:

meropenem

MHB:

Mueller Hinton II Broth

MLVs:

the multilamellar vesicles

MIC:

minimum inhibitory concentration

MPS:

the mononuclear phagocytic system

NBS:

normal bovine serum

NCCLS:

National Committee for Clinical Laboratory Standards

OPA:

o-phthaldialdehyde

PBS:

phosphate-buffered solution

PC:

phosphatidylcholine

PI:

phosphatidyl inositiol

SA:

octadecylamine

ULVs:

unilamellar vesicles

References

  1. 1.

    Mayer, L.D., Bally, M.B., Loughrey, H., Masin, D. and Cullis, P.R. Liposomal vincistine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors. Cancer Res. 50 (1990) 575–579.

  2. 2.

    Mayer, L.D., Bally, M.B., Cullis, P.R., Wilson, S.L. and Emerman, J.T. Comparison of free and liposome encapsulated doxorubicin tumor uptake and antitumor efficacy in the SC115 murine mammary tumor. Cancer Lett. 53 (1990) 183–190.

  3. 3.

    De Marie, S., Janknegt, R. and Bakker-Woudenberg, I.A.J.M. Clinical use of liposomal and lipid complexes amphotericin B. J. Antimicrob. Chemother. 33 (1994) 907–916.

  4. 4.

    Patterson, T.F., and Andrioli, V.T. The role of liposomal amphotericin B in the treatment of systemic fungal infections. Eur. J. Cancer Oncol. 25 (1989) 63–68.

  5. 5.

    Bakker-Woudenberg, I.A.J.M. Delivery of antimicrobials to infected tissue macrophages. Adv. Drug Deliv. Rev. 17 (1995) 5–20.

  6. 6.

    Pinto-Alphandary, H., Andremont, A. and Couvreur, P. Targeted delivery of antibiotics using liposomes and nanoparticles: research and applications. Int. J. Antimicrob. Agents 13 (2000) 155–168.

  7. 7.

    Omri, A., Suntres, Z.E. and Shek, P.N. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 64 (2002) 1407–1413.

  8. 8.

    Sachetelli, S., Beaulac, C., Riffon, R. and Lagace, J. Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomaltobramycin formulation for the treatment of chronic infections in lungs. Biochim. Biophys. Acta 1428 (1999) 334–340.

  9. 9.

    Schiffelers, R., Storm, G. and Bakker-Woudenberg, I.A.J.M. Host factors influencing the preferential localization of sterically stabilized liposomes in Klebsiella pneumoniae-infected rat lung tissue. Pharmaceutic. Res. 18 (2001) 780–787.

  10. 10.

    Schiffelers, R., Storm, G. and Bakker-Woudenberg, I.A.J.M. Liposomeencapsulated aminoglycosides in pre-clinical and clinical studies. J. Antimicrob. Chemother. 48 (2001) 333–344.

  11. 11.

    Webb, M.S., Boman, N.L., Wiseman, D.J., Saxon, D., Sutton, K., Wong, K.F., Logan, P. and Hope, M.J. Antibacterial efficacy against an in vivo Salmonella typhimurium infection model and pharmacokinetics of a liposomal ciprofloxacin formulation. Antimicrob. Agents Chemother. 42 (1998) 45–52.

  12. 12.

    Beaulac, C., Clement-Major, S., Hawari, J. and Lagace, J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob. Agents Chemother. 40 (1996) 665–669.

  13. 13.

    Schiffelers, R., Storm, G., Ten Kate, M.T. and Bakker-Woudenberg, I.A.J.M. Therapeutic efficacy of liposome-encapsulated gentamicin in rat Klebsiella pneumoniae pneumonia in relation to impaired host defence and low bacterial susceptibility to gentamicin. Antimicrob. Agents Chemother. 45 (2001) 464–470.

  14. 14.

    Desai, T.R., Tyrrell, G.J., Ng, T. and Finlay, W.H. In vitro evaluation of nebulization properties, antimicrobial activity, and regional airway surface liquid concentration of liposomal polymyxin B sulfate. Pharmaceutic. Res. 20 (2003) 442–447.

  15. 15.

    Deol, P. and Khuller, G.K. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta 1334 (1997) 161–172.

  16. 16.

    Labana, S., Pandey, R., Sharma, S. and Khuller, G.K. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicrob. Agents 20 (2002) 301–304.

  17. 17.

    Mehta, R.T., Keyhani, A., McQueen, T.J., Rosenbaum, B., Rolston, K.V. and Tarrand, J.J. In vitro activities of free and liposomal drugs against Mycobacterium avium-M. intracellulare complex and M. tuberculosis. Antimicrob. Agents Chemother. 37 (1993) 2584–2587.

  18. 18.

    Duzgunes, N., Flasher, D., Venkata Reddy, M., Luna-Herrera, J., Pattisapu, R. and Gangadharam, J. Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin. Antimicrob. Agents Chemother. 40 (1996) 2618–2621.

  19. 19.

    Cordeiro, C., Wiseman, D.J., Lutwyche, P., Uh, M., Evans, J.C., Finlay, B.B. and Webb, M.S. Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar Typhimurium intracellular infection model. Antimicrob. Agents Chemother. 44 (2000) 533–539.

  20. 20.

    Lutwyche, P., Cordeiro, C., Wiseman, D.J., St-Louis, M., Uh, M., Hope, M.J., Webb, M.S. and Finlay, B.B. Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes. Antimicrob Agents Chemother. 42 (1998) 2511–2520.

  21. 21.

    Magallanes, M., Dijkstra, J. and Fierer, J. Liposome-incorporated ciprofloxacin in the treatment of murine salmonellosis. Antimicrob. Agents Chemother. 37 (1993) 2293–2297.

  22. 22.

    Wong, J.P., Yang, H., Blasetti, K.L., Schnell, G., Conley, J. and Schofield, L.N. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 92 (2003) 265–273.

  23. 23.

    Bakker-Woudenberg, I.A.J.M, Lokerse, A.F., Roerdink, F.H., Regts, D. and Michel, M.F. Free versus liposome-entrapped ampicillin in treatment of infection due to Listeria monocytogenes in normal and athymic (nude) mice. J. Infect. Dis. 151 (1985) 917–924.

  24. 24.

    Sanderson, N.M. and Jones, M.N. Interaction of cationic liposomes with skin bacteria. Biochem Soc. Trans. 23 (1995) 561S.

  25. 25.

    Sanderson, N.M., Guo, B., Jacob, A.E., Handley, P.S., Cunniffe, J.G. and Jones, M.N. The interaction of cationic liposomes with the skin-associated bacterium Staphylococcus epidermidis: effects of ionic strength and temperature. Biochim. Biophys. Acta 1283 (1996) 207–214.

  26. 26.

    Jones, M.N., Francis, S.E., Hutchinson, F.J. and Lyle, I.G. Targeting and delivery of bactericide to adsorbed oral bacteria by use of proteoliposomes. Biochim Biophys. Acta 1147 (1993) 251–261.

  27. 27.

    Beaulac, C., Clement-Major, S., Hawari, J. and Lagace, J. In vitro kinetics of drug release and pulmonary retention of microencapsulated antibiotic in liposomal formulations in relation to the lipid composition. J. Microencapsul. 14 (1997) 335–348.

  28. 28.

    Beaulac, C., Sachetelli, S. and Lagace, J. In vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against Gramnegative and Gram-positive bacteria. J. Antimicrob. Chemother. 41 (1998) 35–41.

  29. 29.

    Furneri, P.M., Fresta, M., Puglisi, G. and Tempera, G. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria. Antimicrob. Agents Chemother. 44 (2000) 2458–2464.

  30. 30.

    Omri, A. and Ravaoarinoro, M. Preparation, properties and the effects of amikacin, netilmicin and tobramycin in free and liposomal formulations on Gram-negative and Gram-positive bacteria. Int. J. Antimicrob. Agents 7 (1996) 9–14.

  31. 31.

    Puglisi, G., Fresta, M., Mazzone, G., Furneri, P.M. and Tempera, G. Formulation parameters of fluoroquinolone-loaded liposomes and in vitro antimicrobial activity. Int. J. Pharm. 118 (1995) 65–76.

  32. 32.

    Sachetelli, S., Khalil, H., Chen, T., Beaulac, C., Senechal, S. and Lagace, J. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim. Biophys. Acta 1463 (2000) 254–266.

  33. 33.

    Stewart, J.C. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal. Biochem. 104 (1980) 10–14.

  34. 34.

    Dreetz, M., Hamacher, J., Eller J., Bomer, K., Koeppe, P., Schaberg, T. and Lode, H. Serum bactericidal activities and comparative phamakokinetics of meropenem and imipenem-cilastatin. Antimicrob. Agents Chemother. 40 (1996) 105–109.

  35. 35.

    National Committee for Clinical Laboratory Standards. 2000. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. Fifth Edition: Approved Standerd M7-A5. NCCLS, Villanova, Pa, USA.

  36. 36.

    Gregoriadis, G. Fate of injected liposomes: observations on entrapped solute retention vesicle clearance and tissue distribution in vivo. In: Liposomes as Drug Carriers, Recent Trends and Progress, (Gregoriadis, G., Ed.) John Wiley and Sons, Chichester, 1988, 3–18.

  37. 37.

    Krieger, J., Childs, S. and Klimberg, I. UTI treatment using liposomal amikacin (MiKasone®). In Program and Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, 1999. Clinical Microbiology and Infection 5S3, 1999, Abstract P194.

  38. 38.

    Hernandez-Caselles, T., Vera, A., Crespo, F., Villalain, J. and Gomez-Fernandez, J. C. Treatment of Brucella melitensis infection in mice by use of liposome-encapsulated gentamicin. Am. J. Vet. Res. 50 (1989) 1486–1488.

  39. 39.

    Vitas, A.I., Diaz, R. and Gamazo, C. Protective effect of liposomal gentamicin against systemic acute murine brucellosis. Chemotherapy 43 (1997) 204–210.

  40. 40.

    Swenson, C.E., Popescu, M.C. and Ginsberg, R.S. Preparation and use of liposomes in the treatment of microbial infections. Crit. Rev. Microbiol. 15 (1988) 1–31.

  41. 41.

    Drulis-Kawa Z., Gubemator, J., Kostyn, K., Doroszkiewicz W., and Kozubek, A. Liposome-encapsulated carbapenems. Cell. Mol. Biol. Lett. 7 (2002) 281.

  42. 42.

    Drulis-Kawa Z., Gubernator, J., Dorotkiewicz-Jach, A., Doroszkiewicz W., and Kozubek, A. In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains. Int. J. Pharm. 315 (2006) 59–66.

  43. 43.

    Sihorkar, V. and Vyas, S.P. Biofilm consortia on biomedical and biological surfaces: delivery and targeting strategies. Pharmaceutic. Res. 18 (2001) 1247–1254.

Download references

Author information

Correspondence to Zuzanna Drulis-Kawa.

Rights and permissions

Reprints and Permissions

About this article

Key words

  • Liposomes
  • Meropenem
  • Gentamicin
  • Bacteria